This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ito, M. Articles by Itoh, K. Search for Related Content PubMed PubMed Citation Articles by Ito, M. Articles by Itoh, K.

Molecular Basis of T Cell-mediated Recognition of Pancreatic Cancer Cells¹

Department of Immunology, Kurume University School of Medicine, Kurume 830-0011 [M. I., S. S., N. T., M. O., N. H., K. I.]; First Department of Surgery, Chiba University School of Medicine, Chiba 260-8670 [M. I.]; and Department of Surgery, National Cancer Center Hospital East, Chiba 277-8577 [N. S.], Japan

Pancreatic cancer continues to be a major unsolved health problem in the world. The prognosis of pancreatic cancer is extremely poor with a median survival of 3–4 months and the 5-year survival being 1–4%. This poor prognosis is primarily because of a lack of effective therapies, and thus development of new treatment modalities is needed. One of these treatments could involve specific immunotherapy, for which elucidation of the molecular basis of T cell-mediated recognition of cancer cells is required. We report here six different genes and 19 immunogenic epitopes from pancreatic adenocarcinoma cells and T-cell receptor ß usage of HLA-A2-restricted CTL clones reacting to some of these epitopes. Sixteen of 19 epitopes were found to possess the ability to induce HLA-A2-restricted CTL activity in the peripheral blood lymphocytes of patients with pancreatic and also colon adenocarcinomas. These results should provide a scientific basis for the development of specific immunotherapy for pancreatic and colon cancer patients.

This article has been cited by other articles:

				K. Imai, S. Hirata, A. Irie, S. Senju, Y. Ikuta, K. Yokomine, M. Harao, M. Inoue, T. Tsunoda, S. Nakatsuru, et al. Identification of a Novel Tumor-Associated Antigen, Cadherin 3/P-Cadherin, as a Possible Target for Immunotherapy of Pancreatic, Gastric, and Colorectal Cancers Clin. Cancer Res., October 15, 2008; 14(20): 6487 - 6495. [Abstract] [Full Text] [PDF]

				C Bauer, F Bauernfeind, A Sterzik, M Orban, M Schnurr, H A Lehr, S Endres, A Eigler, and M Dauer Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model Gut, September 1, 2007; 56(9): 1275 - 1282. [Abstract] [Full Text] [PDF]

				B.-H. Lee, W. Chen, S. Stippec, and M. H. Cobb Biological Cross-talk between WNK1 and the Transforming Growth Factor beta-Smad Signaling Pathway J. Biol. Chem., June 22, 2007; 282(25): 17985 - 17996. [Abstract] [Full Text] [PDF]

				F. H. Schmitz-Winnenthal, C. Volk, K. Z'graggen, L. Galindo, D. Nummer, Y. Ziouta, M. Bucur, J. Weitz, V. Schirrmacher, M. W. Buchler, et al. High Frequencies of Functional Tumor-Reactive T Cells in Bone Marrow and Blood of Pancreatic Cancer Patients Cancer Res., November 1, 2005; 65(21): 10079 - 10087. [Abstract] [Full Text] [PDF]

				N. Yajima, R. Yamanaka, T. Mine, N. Tsuchiya, J. Homma, M. Sano, T. Kuramoto, Y. Obata, N. Komatsu, Y. Arima, et al. Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma Clin. Cancer Res., August 15, 2005; 11(16): 5900 - 5911. [Abstract] [Full Text] [PDF]

				Y. Yoshitake, T. Nakatsura, M. Monji, S. Senju, H. Matsuyoshi, H. Tsukamoto, S. Hosaka, H. Komori, D. Fukuma, Y. Ikuta, et al. Proliferation Potential-Related Protein, an Ideal Esophageal Cancer Antigen for Immunotherapy, Identified Using Complementary DNA Microarray Analysis Clin. Cancer Res., October 1, 2004; 10(19): 6437 - 6448. [Abstract] [Full Text] [PDF]

				S. Shichijo, K. Azuma, N. Komatsu, M. Ito, Y. Maeda, Y. Ishihara, and K. Itoh Two Proliferation-Related Proteins, TYMS and PGK1, Could Be New Cytotoxic T Lymphocyte-Directed Tumor-Associated Antigens of HLA-A2+ Colon Cancer Clin. Cancer Res., September 1, 2004; 10(17): 5828 - 5836. [Abstract] [Full Text] [PDF]

				T. Sasada, H. Takedatsu, K. Azuma, M. Koga, Y. Maeda, S. Shichijo, H. Shoumura, T. Hirai, A. Takabayashi, and K. Itoh Immediate Early Response Gene X-1, a Stress-Inducible Antiapoptotic Gene, Encodes Cytotoxic T-Lymphocyte (CTL) Epitopes Capable of Inducing Human Leukocyte Antigen-A33-Restricted and Tumor-Reactive CTLs in Gastric Cancer Patients Cancer Res., April 15, 2004; 64(8): 2882 - 2888. [Abstract] [Full Text] [PDF]

				M. Harada, R. Gohara, S. Matsueda, A. Muto, T. Oda, Y. Iwamoto, and K. Itoh In Vivo Evidence That Peptide Vaccination Can Induce HLA-DR-Restricted CD4+ T Cells Reactive to a Class I Tumor Peptide J. Immunol., February 15, 2004; 172(4): 2659 - 2667. [Abstract] [Full Text] [PDF]

				T. Mine, Y. Sato, M. Noguchi, T. Sasatomi, R. Gouhara, N. Tsuda, S. Tanaka, H. Shomura, K. Katagiri, T. Rikimaru, et al. Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses Clin. Cancer Res., February 1, 2004; 10(3): 929 - 937. [Abstract] [Full Text] [PDF]

				C. Maccalli, Y. F. Li, M. El-Gamil, S. A. Rosenberg, and P. F. Robbins Identification of a Colorectal Tumor-Associated Antigen (COA-1) Recognized by CD4+ T Lymphocytes Cancer Res., October 15, 2003; 63(20): 6735 - 6743. [Abstract] [Full Text] [PDF]

				K. Azuma, S. Shichijo, Y. Maeda, T. Nakatsura, Y. Nonaka, T. Fujii, K. Koike, and K. Itoh Mutated p53 Gene Encodes a Nonmutated Epitope Recognized by HLA-B*4601-restricted and Tumor Cell-reactive CTLs at Tumor Site Cancer Res., February 15, 2003; 63(4): 854 - 858. [Abstract] [Full Text] [PDF]

				B.-e Xu, X. Min, S. Stippec, B.-H. Lee, E. J. Goldsmith, and M. H. Cobb Regulation of WNK1 by an Autoinhibitory Domain and Autophosphorylation J. Biol. Chem., December 6, 2002; 277(50): 48456 - 48462. [Abstract] [Full Text] [PDF]